ReviewHuman vaccines & immunotherapeutics2013
Pneumococcal vaccination of older adults: conjugate or polysaccharide?
Review in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: A meta-analysis.Human vaccines & immunotherapeutics · 2016Pooled it
- Association between introduction of 13-valent pneumococcal conjugate vaccine and burden of hospitalized adult pneumococcal disease in Taiwan - a retrospective database study.Epidemiology and infection · 2026Article
- Streptococcus pneumoniae serotype distribution in Bangladeshi under-fives with community-acquired pneumonia pre-10-valent pneumococcal conjugate vaccination.Pneumonia (Nathan Qld.) · 2024Article
- Pneumonia and Streptococcus pneumoniae vaccine.Archives of pharmacal research · 2017Review
- Theory and strategy for Pneumococcal vaccines in the elderly.Human vaccines & immunotherapeutics · 2016Article
- Distribution of serotypes and antibiotic susceptibility patterns among invasive pneumococcal diseases in Saudi Arabia.Annals of laboratory medicine · 2014Article
- Pneumococcal vaccination of older adults: conjugate or polysaccharide?Human vaccines & immunotherapeutics · 2014Article
- Preventing non bacteremic pneumococcal pneumonia in older adults: historical background and considerations for choosing between PCV13 and PPV23.Human vaccines & immunotherapeutics · 2014Article
- Role of pneumococcal vaccination in prevention of pneumococcal disease among adults in Singapore.International journal of general medicine · 2014Review
- Risk factors and comorbidities for invasive pneumococcal disease in Western Australian Aboriginal and non-Aboriginal people.Pneumonia (Nathan Qld.) · 2014Article
- Initial effects of the National PCV7 Childhood Immunization Program on adult invasive pneumococcal disease in Israel.PloS one · 2014Article
- Pneumococcal conjugate vaccination for older adults: Reply letter to Hollingsworth et al.Human vaccines & immunotherapeutics · 2014Article
- Theoretical pneumococcal vaccine coverage: analysis of serotypes isolated from inpatients at a tertiary care hospital.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e TisilogiaArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive pneumococcal disease continues to be important problem for older adults. Pneumococcal polysaccharide vaccine (PPV23) has a clinical effectiveness of 43-81%, and following primary vaccination and revaccination, antibody responses last 5-10 y. Hyporesponsiveness to a second dose of vaccine has not been shown to be a significant problem. The use of pneumococcal conjugate vaccines (initially PCV7; more recently PCV13) has led to a dramatic fall in the incidence of conjugate vaccine-type invasive pneumococcal disease in children. Because PCVs are immunogenic in older adults, the question has arisen as to whether to also use PCVs in this age group. However, PCV vaccination of children has also reduced the incidence of conjugate vaccine-serotype disease in older adults, and so wherever PCVs are used in children, there is no epidemiological reason to vaccinate older adults with PCV. The cost-effectiveness of PPV for older adults has changed wherever PCVs have been used for children, and this needs to be periodically re-evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.